Y
Ying Xu
Researcher at Chengdu Medical College
Publications - 56
Citations - 446
Ying Xu is an academic researcher from Chengdu Medical College. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 8, co-authored 22 publications receiving 177 citations.
Papers
More filters
Journal ArticleDOI
Characterization of carbapenem-resistant Acinetobacter baumannii isolates in a Chinese teaching hospital.
Yaowen Chang,Guangxin Luan,Ying Xu,Yanhong Wang,Min Shen,Chi Zhang,Wei Zheng,Jinwei Huang,Jingni Yang,Xu Jia,Baodong Ling +10 more
TL;DR: It is indicated that rational application of antibiotics is indispensable for minimizing widespread of drug resistance in CRAB, and CC92 A. baumannii carrying OXA-23 is a major drug-resistant strain spreading in China.
Journal ArticleDOI
Serum klotho protein levels and their correlations with the progression of type 2 diabetes mellitus
TL;DR: Serum levels of α-KLotho and β-Klotho are down-regulated in patients with type 2 diabetes mellitus, and the positive correlation of α/ β/Kloths levels indicates that they might have similar mechanisms in T2DM.
Journal ArticleDOI
miR-324-3p reverses cisplatin resistance by inducing GPX4-mediated ferroptosis in lung adenocarcinoma cell line A549.
Shi-Hua Deng,Dong-Ming Wu,Li Li,Teng Liu,Ting Zhang,Jing Li,Ye Yu,Miao He,Yang-Yang Zhao,Rong Han,Ying Xu +10 more
TL;DR: In this article, the effect of miR-324-3p on lung adenocarcinoma cell line A549 resistant to cis-diamminedichloroplatinum II (DDP), aka cisplatin was investigated.
Journal ArticleDOI
Bixin Attenuates Experimental Autoimmune Encephalomyelitis by Suppressing TXNIP/NLRP3 Inflammasome Activity and Activating NRF2 Signaling.
TL;DR: It is found that bixin significantly improved the symptoms and pathology in EAE mice, reduced the release of inflammatory cytokines TNF-α,IL-6, IL-8, Il-17, and IFN-γ, and increased the expression of the anti-inflammatory cytokine IL-10, and taken together these results indicate thatbixin is a promising therapeutic candidate for treatment of MS.
Journal ArticleDOI
PLEK2 mediates metastasis and vascular invasion via the ubiquitin-dependent degradation of SHIP2 in non-small cell lung cancer
Dong-Ming Wu,Shi-Hua Deng,Jing Zhou,Rong Han,Teng Liu,Ting Zhang,Jing Li,Jian‐ping Chen,Ying Xu +8 more
TL;DR: PLEK2 could be a novel prognostic marker and potential therapeutic target for NSCLC metastasis and vascular invasion, and is found to directly interact with SHIP2 and target it for ubiquitination and degradation inNSCLC cells.